Navigation Links
Caliper Awarded Additional Task Order for EPA ToxCast Program
Date:5/14/2010

HOPKINTON, Mass., May 14 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $2.9 million under its contract with the Environmental Protection Agency (EPA) for the EPA's ToxCast screening program.  Together with an initial Phase II task order awarded in November 2009, this new task order increases the cumulative funding Caliper has been awarded under Phase II of the ToxCast program to $4.7 million.  

"This latest EPA task order improves the visibility we have for achieving our CDAS unit revenue projections in the second half of 2010, and should provide us good momentum into 2011," commented Kevin Hrusovsky, President and CEO of Caliper.

The long term goal of the EPA's ToxCast program is to identify in vitro assays that can predict the toxicity of chemical compounds in humans and animals, by comparing the results of in vitro testing conducted by Caliper and others with the toxicity data in the EPA's in vivo toxicity database, ToxRefDB, and then to employ those predictive tests to supplement or replace existing animal-based tests reducing cost and improving the speed of regulatory approval of new environmental chemicals.

"Phase II of the ToxCast program will involve screening another 700 environmental compounds through a wide set of assays. We expect to begin the Phase II effort within the next several months after the Phase II compound library is delivered to us by the EPA," commented David Manyak, Executive Vice President, Drug Discovery Services. "Our work with the EPA is a strong validation of our services and the industry is taking notice. We have seen increased interest from the pharmaceutical, chemical, and cosmetic industries in CDAS commercial services based on in vitro toxicology assays represented in the ToxCast panel."

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease.  Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including statements regarding Caliper's expectations regarding its future role in the EPA's ToxCast program, Caliper's belief that its funded activities under the ToxCast program will continue to expand, and Caliper's belief that the recently received task order from the EPA improves the visibility it has for achieving its CDAS unit revenue projections in the second half of 2010, and should provide good momentum into 2011,  are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that the EPA may stop or curtail funding under its ToxCast screening program, Caliper may experience unexpected delays in its receipt of compounds from the EPA for testing under the ToxCast program, and Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its drug discovery and imaging systems and other products. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2009. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov.  Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

NOTE:  Caliper is a registered trademark of Caliper Life Sciences, Inc.  ToxCast is a trademark of the Environmental Protection Agency.  


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at Deutsche Banks 35th Annual Health Care Conference
2. Caliper Life Sciences Launches LabChip(R) XT for Next Generation Sequencing Applications
3. Caliper Life Sciences Launches Living Image(R) 4.0 Software
4. Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems
5. Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray
6. Caliper Life Sciences Reports Second Quarter 2009 Results
7. Caliper Life Sciences Second Quarter 2009 Financial Results Conference Call Notice
8. Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analysis
9. Caliper Life Sciences to Webcast Investor Session of Open House
10. Caliper Life Sciences Reports First Quarter 2009 Results
11. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... According to a report by Transparency Market Research (TMR), ... the presence of a large pool of participants; however, only a ... Sigma-Aldrich, compete with each other in this market. With Proliant being ... of this market in 2016.  ... As of now, a large number of vendors are ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... closer look at four equities in the Biotech industry: ... EYEG), Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus ... March 21 st , 2017, Credit Suisse upgraded its rating ... stocks by downloading their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):